Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The minimally-invasive extracorporeal shockwave lithotripsy (ESWL) procedure is generally
considered the best first-line treatment option for most adults and children with
nephrolithiasis, especially when the calculi are smaller than 2 cm in size. Despite some
promising results, few clinical trials have assessed the impact of furosemide on the outcome
of ESWL. This study seeks to determine the effect of furosemide on ESWL outcomes when
treating renal and ureteral calculi, hypothesizing that it will result in better outcomes for
patients.
The present double-blind, randomized clinical trial includes 500 adults aged 18-60 years
referring to the ESWL Clinic of Shahid Faghihi Hospital. Using block randomization, the
patients are randomly assigned to one of two groups. All patients are to receive sedation
with intravenous midazolam and 1000 ml of normal saline 30 minutes before ESWL. The only
difference between the groups is that in the furosemide group, 40 mg of furosemide is added
to the normal saline in the drug preparation room before administration. All patients are
kept under heart monitoring and pulse oximetry until recovery. Pain will be checked for all
participants via a telephone interview 24 hours later. The outcomes and possible side effects
of ESWL will be evaluated for all patients after two and twelve weeks.